Methods and compositions for treating pancreatic cancer
A dual GSK3-β and HDAC inhibitor, like Compound 1, targets multiple signaling pathways in pancreatic cancer to overcome resistance, enhancing chemotherapy sensitivity and efficacy by inhibiting tumor-promoting pathways and EMT, addressing the aggressive nature of PDAC.
Patent Information
- Application Number
- PCT/US2025/029375
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-05-14
- Filing Date
- 2025-05-14
- Publication Date
- 2025-11-20
AI Technical Summary
Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), is highly aggressive and often resistant to systemic therapies due to genetic and cellular changes, leading to challenges in increasing cancer cell sensitivity to therapy, especially when single targeted inhibitor therapies fail to address complex redundant signaling pathways.
Administering a pharmaceutical composition comprising a glycogen synthase kinase-3 beta (GSK3-β) inhibitor and a histone deacetylase (HDAC) inhibitor, such as Compound 1, to target multiple key signaling pathways, including those associated with increased expression or function of GATA, KRT17, TP56, or CYP3A genes or proteins, to enhance sensitivity to chemotherapy.
The combination of GSK3-β and HDAC inhibitors, like Compound 1, synergistically increases the sensitivity of pancreatic cancer cells to chemotherapeutic agents, enhancing treatment efficacy by inhibiting tumor-promoting pathways and interfering with epithelial to mesenchymal transition, thereby improving treatment outcomes.